干白素-17A通过升调肝细胞癌中编程死亡联体-1表达来促进瘤的进展
Zhong-Xia Yang1,2, Li-Ting Zhang1, Xiao-Jun Liu3
1The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, Gansu Province, China.
World journal of gastrointestinal oncology
|January 16, 2025
概括
干白素-17A (IL-17A) 在肝细胞癌 (HCC) 中高调节编程死亡配体1 (PD-L1),促进瘤的进展. 阻断IL-17A增强了HCC模型中的PD-L1免疫治疗疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 肝细胞癌 (HCC) 是一种与炎症相关的癌症,预后不佳.
- 免疫疗法是HCC的关键治疗方法,由瘤微环境的炎症状态调节.
- 干白素-17A (IL-17A) 影响瘤进展和免疫检查点分子表达.
研究的目的:
- 研究IL-17A如何影响HCC中的PD-L1表达.
- 为了阐明底层的分子机制.
- 为了确定HCC.潜在的治疗策略.
主要方法:
- 评估IL-17A诱导的PD-L1上调,使用RT-PCR,西部抹杀和流细胞计.
- 利用基因淘汰模型和途径抑制剂来研究机制.
- 通过共同培养系统和体外细胞行为评估IL-17A在免疫逃避中的作用.
- 在HCC小鼠模型中测试IL-17A和PD-L1抑制剂.
主要成果:
- 通过IL-17AR/p-SMAD2通路,IL-17A剂量依赖地通过HCC细胞增加PD-L1的表达.
- IL-17A促进了HCC细胞的存活,增殖,迁移,并改变了关键基因的表达 (VEGF,MMP9,BCL-1,BAX).
- 结合IL-17A和PD-L1抑制在体内显示出协同作用的抗瘤作用和增加CD8+ T细胞透.
结论:
- 通过IL-17AR/p-SMAD2信号通路对PD-L1进行上调,IL-17A驱动HCC的进展.
- 阻断IL-17A可以提高PD-L1向免疫治疗在HCC中的疗效.
- 向IL-17A是一种有前途的策略,可以改善HCC治疗结果.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.2K
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
相关概念视频
T Cell Types and Functions
946
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
946
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Tumor Immunotherapy
469
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
469
The Intrinsic Apoptotic Pathway
6.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.3K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
